60,432 Shares in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Acquired by Anchor Capital Advisors LLC

Anchor Capital Advisors LLC bought a new position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 60,432 shares of the company’s stock, valued at approximately $805,000. Anchor Capital Advisors LLC owned 0.23% of Eton Pharmaceuticals at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. bought a new stake in Eton Pharmaceuticals during the 3rd quarter worth approximately $54,000. Jane Street Group LLC bought a new stake in Eton Pharmaceuticals during the 3rd quarter worth approximately $90,000. Baader Bank Aktiengesellschaft bought a new stake in Eton Pharmaceuticals during the 4th quarter worth approximately $373,000. Connor Clark & Lunn Investment Management Ltd. raised its stake in Eton Pharmaceuticals by 86.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock worth $390,000 after acquiring an additional 30,167 shares during the period. Finally, Wasatch Advisors LP bought a new stake in Eton Pharmaceuticals during the 3rd quarter worth approximately $1,431,000. Institutional investors own 27.86% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on ETON. B. Riley began coverage on shares of Eton Pharmaceuticals in a research note on Friday, January 10th. They set a “buy” rating and a $21.00 target price on the stock. Craig Hallum lifted their price objective on shares of Eton Pharmaceuticals from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Finally, HC Wainwright lifted their price objective on shares of Eton Pharmaceuticals from $17.00 to $33.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd.

Eton Pharmaceuticals Price Performance

Eton Pharmaceuticals stock opened at $15.70 on Friday. The stock has a market cap of $409.00 million, a P/E ratio of -71.36 and a beta of 1.40. Eton Pharmaceuticals, Inc. has a 1 year low of $3.03 and a 1 year high of $18.41. The firm’s 50 day moving average price is $14.96 and its 200-day moving average price is $10.37.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.